Compare SAIC & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAIC | CRNX |
|---|---|---|
| Founded | 1969 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.9B |
| IPO Year | 2013 | 2018 |
| Metric | SAIC | CRNX |
|---|---|---|
| Price | $101.84 | $35.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $110.50 | $76.75 |
| AVG Volume (30 Days) | 554.8K | ★ 850.3K |
| Earning Date | 06-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | ★ 7.39 | N/A |
| EPS | ★ 2.61 | N/A |
| Revenue | ★ $7,262,000,000.00 | $1,039,000.00 |
| Revenue This Year | N/A | $720.10 |
| Revenue Next Year | $1.65 | $184.67 |
| P/E Ratio | $39.21 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $81.08 | $25.83 |
| 52 Week High | $123.41 | $57.99 |
| Indicator | SAIC | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 42.22 | 51.40 |
| Support Level | $92.46 | $33.15 |
| Resistance Level | $115.25 | $44.89 |
| Average True Range (ATR) | 4.85 | 1.56 |
| MACD | -1.38 | 0.33 |
| Stochastic Oscillator | 4.06 | 79.51 |
Science Applications International Corp provides technical, engineering, and enterprise IT services mainly to the U.S. government. Specifically, it offers end-to-end solutions spanning the design, development, integration, deployment, management and operations, sustainment, and security of the customer's entire IT infrastructure. The company has two reportable segments which include Defense and Intelligence and the Civilian segment. Maximum revenue is generated from its Defense and Intelligence segment, which provides a diverse portfolio of national security solutions to the Department of Defence (DoD) and the Intelligence Community of the United States Government. The Civilian segment provides solutions to the civilian markets, encompassing federal, state, and local governments.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.